Activity of a novel series of acylides active against community-acquired respiratory pathogens

International Journal of Antimicrobial Agents

Volumn 36, Issue 2, 2010, Pages 169-174

  Pandya, Manisha ^a   Chakrabarti, Anjan ^a   Rathy, Sujata ^a   Katoch, Rita ^a   Venkataraman, R ^a   Bhateja, Pragya ^a   Mathur, Tarun ^a   Kumar, G Ram ^a   Malhotra, Sunita ^a   Rao, Madhvi ^a   Bhadauria, Tripti ^a   Barman, Tarani Kanta ^a   Das, Biswajit ^a   Upadhyay, Dilip ^a   Bhatnagar, Pradip Kumar ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Community acquired respiratory tract infections; Haemophilus influenzae; Macrolides; Moraxella catarrhalis; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAMIC ACID; CLARITHROMYCIN; CLARITHROMYCIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; NITROGEN; PENICILLIN G; RBX 10000020; RBX 10000064; RBX 10000132; RBX 10000138; RBX 10000149; RBX 10000296; RBX 10000615; RBX 10000974; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BRONCHOPNEUMONIA; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG EVALUATION, PRECLINICAL; HAEMOPHILUS INFLUENZAE; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 77953808716     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.026     Document Type: Article

References (15)

1. Buxbaum A., Forsthuber S., Graninger W., Georgopoulos A. Comparative activity of telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 2003, 52:371-374.
2. Ackermann G., Rodloff A.C. Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J Antimicrob Chemother 2003, 51:497-511.
3. Lutfiyya M.N., Henley E., Chang L.F. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 2006, 73:442-450.
4. Reinert R.R. The antimicrobial profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009, 15(Suppl. 3):7-11.
5. Farrell D.J., Morrissey I., Bakker S., Buckridge S., Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004, 48:3169-3171.
6. Leclercq R., Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002, 46:2727-2734.
7. Abbanat D., Webb G., Foleno B., Li Y., Macielag M., Montenegro D., et al. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides. Antimicrob Agents Chemother 2005, 48:309-315.
8. Azoulay-Dupuis E., Mohler J., Bédos J.P., Barau C., Fan B. Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model. Antimicrob Agents Chemother 2006, 50:3033-3038.
9. Tanikawa T., Asaka T., Kashimura M., Misawa Y., Suzuki K., Sato M., et al. Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics. J Med Chem 2001, 44:4027-4030.
10. Wolter N., Smith A.M., Low D.E., Klugman K.P. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007, 51:1092-1095.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
12. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
13. Davies T.A., Dewasse B.E., Jacobs M.R., Appelbaum P.C. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000, 44:414-417.
14. Reinert R.R., Al-Lahham A. Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22. Antimicrob Agents Chemother 2005, 49:3011-3013.
15. Banche G., Roana J., Allizond V., Andreotti S., Malabaila A., Li Vigni N., et al. In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. Lett Appl Microbiol 2008, 47:309-314.